Ananth has more than 20 years’ experience in pharmaceutical consulting across a variety of disciplines, including quantitative systems pharmacology modeling, health economic modeling, systemic literature reviews, indirect treatment comparisons, and complex statistical analyses of clinical and real-world databases required to support regulatory, payer and HTA submissions worldwide.
Ananth Kadambi, PhD
VP, Real World Evidence & Modeling Solutions
関連情報
Beyond Approval: Using Model-Informed Strategies to Maximize the Value of ADCs
ブログ
Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access
オンデマンド・ウェビナー
Why the Most Important Phase 3 Decisions Should Be Made Before Phase 3
ブログ
Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access
ウェビナー
Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy
オンデマンド・ウェビナー
